June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 09, 2025

EHR Prompts Cut Antibiotic Use by 35%

A 92-hospital trial found that simple prompts in electronic health records helped reduce the use of broad-spectrum antibiotics in low-risk abdominal infection cases—without increasing ICU stays or length of hospitalization.

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

New Guidelines Recommend Hypnotherapy, CBT for Pediatric Abdominal Pain

Joint ESPGHAN/NASPGHAN guidance outlines evidence-based treatments for functional abdominal pain and irritable bowel syndrome in pediatric patients.

Conexiant

June 02, 2025

Only 20% Account for 80% of Steroid Use: Study

In a UK-wide analysis of nearly 2 million patients, researchers found that “a fifth of patients receiving corticosteroids accounted for over 80% of oral and inhaled corticosteroid prescribing,” highlighting concentrated use and variable treatment persistence across formulations.

Conexiant

May 29, 2025

Medical Oddities: A New Stress Test Hiding in Floss

From floss to fat loss— this week five clever studies are redefining daily health habits.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant